HC Wainwright Brokers Increase Earnings Estimates for UNCY

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for Unicycive Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($0.11) for the year, up from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark reiterated a “speculative buy” rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $5.13.

Unicycive Therapeutics Price Performance

UNCY stock opened at $0.46 on Monday. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.82. The company has a fifty day simple moving average of $0.43 and a two-hundred day simple moving average of $0.54. The firm has a market capitalization of $47.24 million, a P/E ratio of -0.47 and a beta of 2.29.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently made changes to their positions in the company. Great Point Partners LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $3,491,000. Walleye Capital LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $2,040,000. BVF Inc. IL lifted its holdings in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after acquiring an additional 1,493,462 shares during the last quarter. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $807,000. Finally, Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth about $33,000. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.